Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
Antonio C P Wong, Susanna K P Lau, Greta Santi Laurini, Nicola Montanaro, Domenico Motola
doi:10.3390/jcm12010034
Concerns have been raised about the actual benefit and safety of molnupiravir, a new antiviral treatment for coronavirus disease 2019 . In order to provide additional evidence to support its use, we aimed to evaluate the real safety profile based on post-marketing pharmacovigilance data. Molnupiravir safety data were captured from the FDA Adverse Event Reporting System (FAERS). We performed a descriptive analysis of the baseline demographic characteristics of patients who experienced at least one adverse drug reaction (ADRs) related to molnupiravir, and then evaluated those most frequently reported. As of 31 March 2022, 612 reports of ADRs related to molnupiravir were submitted to the FDA, 301 (49.18%) were related to females and 281 (45.92%) to males. Most reports (524; 85.62%) were submitted by healthcare professionals and 345 (56.37%) concerned serious outcomes. The most common reported ADRs were diarrhoea (57; 4.51%), rash (36; 2.85), nausea (29; 2.30%), and COVID-19 pneumonia (22; 1.74%). The most frequent adverse reactions reported with molnupiravir in the U.S. post-marketing experience are consistent with the safety evaluation of the antiviral medicine. Even if no evident safety concerns emerged, an unexpectedly high rate of serious adverse reactions together with a few cases of potential new adverse reactions occurred.
Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
Agostini, Pruijssers, Chappell, Gribble, Lu et al., Small-Molecule Antiviral β-d-N 4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance, J. Virol,
doi:10.1128/JVI.01348-19Alimohamadi, Sepandi, Taghdir, Hosamirudsari, Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis, J. Prev Med. Hyg,
doi:10.15167/2421-4248/jpmh2020.61.3.1530Bernal, Gomes Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients, N. Engl. J. Med,
doi:10.1056/NEJMoa2116044Cascella, Rajnik, Aleem, Dulebohn, Di Napoli et al., Evaluation, and Treatment of Coronavirus (COVID-19
Chen, Zhang, Case, Winkler, Liu et al., Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies, Nat. Med,
doi:10.1038/s41591-021-01294-wDougan, Azizad, Chen, Feldman, Frieman et al., Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19, MedRxiv,
doi:10.1101/2022.03.10.22272100Dougan, Nirula, Azizad, Mocherla, Gottlieb et al., Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2102685Etminan, Re: Molnupiravir's authorisation was premature, BMJ
Gordon, Tchesnokov, Schinazi, Götte, Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template, J. Biol. Chem,
doi:10.1016/j.jbc.2021.100770Grobler, Strizki, Murgolo, Gao, Cao et al., Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies, Open Forum. Infect. Dis,
doi:10.1093/ofid/ofab466.742Gupta, Gonzalez-Rojas, Juarez, Crespo Casal, Moya et al., Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab, N. Engl. J. Med,
doi:10.1056/NEJMoa2107934Hama, Re: Molnupiravir's authorisation was premature, BMJ
Hashemian, Jamaati, Khalili-Pishkhani, Roshanzamiri, Eskandari et al., Molnupiravir in Combination with Remdesivir for Severe COVID-19 Patients Admitted to Hospital: A Case Series, Microbes Infect. Chemother,
doi:10.54034/mic.e1366Hayashi, Molnupiravir might be dangerous without clarification of its indications, BMJ,
doi:10.1136/bmj.o1030Hill, Re: Molnupiravir's authorisation was premature, BMJ
Johnson, Puenpatom, Moncada, Burgess, Duke et al., Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19: A Randomized, Placebo-Controlled Trial, Ann. Intern. Med,
doi:10.7326/M22-0729Kabinger, Stiller, Schmitzová, Dienemann, Kokic et al., Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat. Struct. Mol. Biol,
doi:10.1038/s41594-021-00651-0Mahase, COVID-19: UK becomes first country to authorise antiviral molnupiravir, BMJ,
doi:10.1136/bmj.n2697Mccreary, Bariola, Wadas, Shovel, Wisniewski et al., Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19, JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2022.6920Merck, Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
Painter, Natchus, Cohen, Holman, Painter, Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19, Curr. Opin. Virol,
doi:10.1016/j.coviro.2021.06.003Planas, Saunders, Maes, Guivel-Benhassine, Planchais et al., Considerable escape of SARS-CoV-2 Omicron to antibody neutralization, Nature,
doi:10.1038/s41586-021-04389-zStreinu-Cercel, Săndulescu, Preotescu, Kim, Kim et al., Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease, Open Forum. Infect. Dis,
doi:10.1093/ofid/ofac053Tarnawski, Ahluwalia, Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs, World J. Gastroenterol,
doi:10.3748/wjg.v28.i3.275Thorlund, Sheldrick, Meyerowitz-Katz, Singh, Hill, Making Statistical Sense of the Molnupiravir MOVe-OUT, Clin. Trial. Am. J. Trop Med. Hyg,
doi:10.4269/ajtmh.21-1339Yücel, A case of acute renal failure with COVID-19 under Molnupiravir treatment, Med. Sci. Discov
Zhou, Hill, Sarkar, Tse, Woodburn et al., β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, J. Infect. Dis,
doi:10.1093/infdis/jiab247
